October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will be featured at the 2020 Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held virtually October 24 to 28, 2020.

October 25, 2020 — Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.

October 25, 2020 —RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, will present eight clinical abstracts evaluating the use

October 24, 2020 — A study from Winship Cancer Institute of Emory University (Winship) has the potential to change how patients whose prostate cancer recurs after prostatectomy are treated. The study will be featured in both the plenary session and press program of the American Society for Radiation Oncology (ASTRO) Annual Meeting on Monday, October 26.

October 24, 2020 — The American Society of Radiation Oncology's (ASTRO) 62nd Annual Meeting launched its Exhibit Hall Only Day yesterday, a new event one day before programming begins, to provide more time for attendees to network and interact with exhibitors. More than 1,000 attendees from 60 countries participated in Exhibit Hall Only Day yesterday, visiting our more than 110 exhibitors.

October 24, 2020 — An estimated 1.8 million new cancer cases will be diagnosed in the U.S. this year alone. With a disease so prevalent, treatments like radiation therapy are critical, and while planning, clinicians require accuracy, precision and speed.

October 24, 2020 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (

An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from computed tomography (FFR-CT) did not significantly reduce costs, but did reduce the use of invasive coronary angiography (ICA). This study was looking to confirm that FFR-CT use would result in a lowering of costs to care for patients in the U.K. National Health System (NHS).
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now